Uyuşturucuyla Mücadele Dairesi

The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov. The Drug Enforcement Administration (DEA) is the lead Federal agency in enforcing narcotics and controlled substances laws and regulations. DEA also enforces the Federal money laundering and bulk currency smuggling statutes when the funds involved in the transactions or smuggling are derived from the sale of narcotics. It was created in July 1973 by Reorganization Plan No. 2 of 1973 (5 U.S.C. app.). DEA enforces the provisions of the controlled substances and chemical diversion and trafficking laws and regulations of the United States, and operates on a worldwide basis. It presents cases to the criminal and civil justice systems of the United States--or any other competent jurisdiction--on those significant organizations and their members involved in cultivation, production, smuggling, distribution, laundering of proceeds, or diversion of controlled substances appearing in or destined for illegal traffic in the United States. DEA disrupts and dismantles these organizations by arresting their members, confiscating their drugs, and seizing their assets; and creates, manages, and supports enforcement-related programs--domestically and internationally--aimed at reducing the availability of and demand for illicit controlled substances. The "Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act)," which became law on October 24, 2018, amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment for opioid use disorder and expand... The Drug Enforcement Administration (DEA) proposes to revise existing regulations relating to the management of quotas for schedule I and II controlled substances and the list I chemicals, ephedrine, pseudoephedrine, and phenylpropanolamine, to be utilized by DEA- registered manufacturers. This rule is being proposed to: restructure DEA's... The "Protecting Patient Access to Emergency Medications Act of 2017," (the Act) which became law on November 17, 2017, amended the Controlled Substances Act (CSA) to allow for a new registration category for emergency medical services agencies that handle controlled substances. It also established standards for registering emergency medical... by the Drug Enforcement Administration and the Health and Human Services Department on 12/31/2025 . The Drug Enforcement Administration (DEA) jointly with the Department of Health and Human Services (HHS) is issuing a fourth extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026. The Drug Enforcement Administration is proposing the control of phenethyl halides as list I chemicals under the Controlled Substances Act (CSA). Phenethyl halides are important to the illicit manufacture of fentanyl, as well as fentanyl analogues, and fentanyl- related substances as they are often used in synthetic routes to manufacture these... The Drug Enforcement Administration proposes placing the substance tianeptine (7-[(3-chloro-6,11-dihydro-6-methyl-5,5- dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, salts, and salts of...